Gilead Sciences, Inc. (NASDAQ:GILD) Stock Holdings Lessened by Voya Investment Management LLC

Voya Investment Management LLC lowered its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 5.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 816,893 shares of the biopharmaceutical company's stock after selling 50,947 shares during the period. Voya Investment Management LLC owned approximately 0.07% of Gilead Sciences worth $75,456,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. HHM Wealth Advisors LLC grew its stake in Gilead Sciences by 118.5% in the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company's stock valued at $26,000 after acquiring an additional 154 shares during the last quarter. YANKCOM Partnership purchased a new stake in shares of Gilead Sciences in the fourth quarter valued at about $28,000. Decker Retirement Planning Inc. purchased a new stake in shares of Gilead Sciences in the fourth quarter valued at about $29,000. Crews Bank & Trust purchased a new position in shares of Gilead Sciences during the 4th quarter worth approximately $31,000. Finally, Stephens Consulting LLC lifted its stake in Gilead Sciences by 325.0% in the 4th quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company's stock valued at $31,000 after buying an additional 260 shares in the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, April 15th. The shares were sold at an average price of $106.40, for a total transaction of $266,000.00. Following the transaction, the chief financial officer now directly owns 168,174 shares in the company, valued at approximately $17,893,713.60. The trade was a 1.46 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders sold 302,785 shares of company stock worth $30,540,875 in the last quarter. 0.27% of the stock is owned by company insiders.

Gilead Sciences Price Performance

NASDAQ GILD traded up $3.17 on Monday, reaching $106.34. The company's stock had a trading volume of 9,453,782 shares, compared to its average volume of 7,514,594. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50. The firm's 50 day moving average is $109.21 and its two-hundred day moving average is $98.33. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $119.96. The stock has a market cap of $132.41 billion, a PE ratio of 287.41, a PEG ratio of 0.71 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, topping analysts' consensus estimates of $1.77 by $0.04. The firm had revenue of $6.67 billion during the quarter, compared to analysts' expectations of $6.77 billion. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. The firm's revenue for the quarter was down .3% compared to the same quarter last year. During the same period last year, the firm posted ($1.32) earnings per share. As a group, sell-side analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, June 27th. Stockholders of record on Friday, June 13th will be issued a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a dividend yield of 2.97%. The ex-dividend date is Friday, June 13th. Gilead Sciences's dividend payout ratio is 66.53%.

Analyst Ratings Changes

Several brokerages have recently issued reports on GILD. The Goldman Sachs Group upped their price objective on Gilead Sciences from $85.00 to $96.00 and gave the company a "neutral" rating in a research report on Wednesday, February 12th. Royal Bank of Canada boosted their price target on Gilead Sciences from $84.00 to $90.00 and gave the company a "sector perform" rating in a report on Wednesday, February 12th. Wells Fargo & Company raised their price objective on Gilead Sciences from $120.00 to $140.00 and gave the stock an "overweight" rating in a report on Wednesday, March 5th. Morgan Stanley upped their target price on Gilead Sciences from $130.00 to $135.00 and gave the company an "overweight" rating in a research note on Friday. Finally, Cantor Fitzgerald started coverage on Gilead Sciences in a report on Tuesday, April 22nd. They issued an "overweight" rating and a $125.00 price target for the company. Nine research analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $109.43.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.